Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.
2.

Women with BRCA1 or BRCA2 mutations renegotiating a post-prophylactic mastectomy identity: self-image and self-disclosure.

Kenen RH, Shapiro PJ, Hantsoo L, Friedman S, Coyne JC.

J Genet Couns. 2007 Dec;16(6):789-98.

PMID:
17917796
3.

Psychological impact of prophylactic oophorectomy in women at increased risk for ovarian cancer.

Meiser B, Tiller K, Gleeson MA, Andrews L, Robertson G, Tucker KM.

Psychooncology. 2000 Nov-Dec;9(6):496-503.

PMID:
11180584
4.
5.

Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer.

Meiser B, Butow P, Barratt A, Friedlander M, Gattas M, Kirk J, Suthers G, Walpole I, Tucker K.

Gynecol Oncol. 1999 Oct;75(1):122-9.

PMID:
10502438
6.

Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.

Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B.

J Clin Oncol. 2004 Mar 15;22(6):1045-54.

PMID:
14981106
7.
8.

Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.

Gabriel CA, Tigges-Cardwell J, Stopfer J, Erlichman J, Nathanson K, Domchek SM.

Fam Cancer. 2009;8(1):23-8. doi: 10.1007/s10689-008-9208-6.

PMID:
18758995
9.
10.

Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer.

Eisen A, Rebbeck TR, Wood WC, Weber BL.

J Clin Oncol. 2000 May;18(9):1980-95. Review.

PMID:
10784640
11.
12.

Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomy.

Patenaude AF, Orozco S, Li X, Kaelin CM, Gadd M, Matory Y, Mayzel K, Roche CA, Smith BL, Farkas W, Garber JE.

Psychooncology. 2008 Aug;17(8):831-43. doi: 10.1002/pon.1279.

13.

Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.

Schrag D, Kuntz KM, Garber JE, Weeks JC.

JAMA. 2000 Feb 2;283(5):617-24.

PMID:
10665701
14.

The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy.

Tucker PE, Bulsara MK, Salfinger SG, Tan JJ, Green H, Cohen PA.

Maturitas. 2016 Mar;85:42-8. doi: 10.1016/j.maturitas.2015.12.004.

PMID:
26857878
15.

Risk management options elected by women after testing positive for a BRCA mutation.

Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, Raine-Bennett T, Powell CB.

Gynecol Oncol. 2014 Feb;132(2):428-33. doi: 10.1016/j.ygyno.2013.12.014.

PMID:
24355485
16.

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL; PROSE Study Group..

J Clin Oncol. 2005 Nov 1;23(31):7804-10.

PMID:
16219936
17.

Prophylactic oophorectomy: a continuing controversy.

Fong YF, Lim FK, Arulkumaran S.

Obstet Gynecol Surv. 1998 Aug;53(8):493-9. Review.

PMID:
9702789
19.

Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.

Finch A, Narod SA.

Maturitas. 2011 Nov;70(3):261-5. doi: 10.1016/j.maturitas.2011.08.001. Review.

PMID:
21893388
20.

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K.

N Engl J Med. 2002 May 23;346(21):1609-15.

Items per page

Supplemental Content

Support Center